MYC and neoplasm: In glioblastoma (GBM, a malignant glial/astrocytic tumor) cells with activating epidermal growth factor receptor (EGFR) mutations, mTORC1 upregulates the heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) splicing factor, promoting the alternative splicing of Myc-associated factor X (Max) to generate Delta Max, thereby functionally augmenting Myc-dependent glycolytic metabolism and tumor cell proliferation [48].